Free Trial
Ends Tomorrow! Last Chance to Get MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:CALA

Calithera Biosciences Q2 2022 Earnings Results & Report

Calithera Biosciences logo
$0.0001 0.00 (0.00%)
As of 10/28/2026 11:11 AM Eastern

Calithera Biosciences beat analyst earnings expectations in its Q2 2022 results, released August 15, 2022. The company reported EPS of -$1.59 versus the -$2.70 consensus estimate.

Research:Profile

Earnings Announcement Details

Quarter
Q2 2022
Report Date

Calithera Biosciences EPS Results

Actual EPS
-$1.59
Consensus EPS
-$2.70
Beat/Miss
Beat by +$1.11
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Calithera Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Calithera Biosciences' next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

Calithera Biosciences Q2 2022 Earnings FAQ

Calithera Biosciences (NASDAQ:CALA) reported earnings of -$1.59 per share for Q2 2022, beating the consensus estimate of -$2.70. The report was announced on Monday, August 15, 2022.

Calithera Biosciences' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Calithera Biosciences on the company's earnings history page.

Calithera Biosciences Earnings Headlines

Calithera Biosciences (NASDAQ:CALA) Stock Breaks Above 50 Day Moving Average - Here's What Happened
October 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31138434
Calithera Biosciences Inc (CALA)
November 23, 2024  |  investing.comhttps://www.investing.com/equities/calithera-biosciences-inc-balance-sheet
Last note from me on this
Joel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gold, and other assets. The hour long session answers the question every investor faces: when to buy, when to sell, or when to simply hold steady. Sessions run every day, including evenings and early mornings, so there's a slot that fits any schedule.tc pixel
October 29 at 1:00 AM  |  The Cycle Code (Ad)
Christina Cala
August 12, 2023  |  npr.orgN
Calithera Biosciences cancels special meeting due to lack of quorum
June 29, 2023  |  seekingalpha.comhttps://seekingalpha.com/news/3984280-calithera-biosciences-cancels-special-meeting-due-to-lack-of-quorum
CALA - Calithera Biosciences, Inc.
May 31, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/quote/CALA/history
See More Calithera Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Calithera Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calithera Biosciences and other key companies, straight to your email.

About Calithera Biosciences

Calithera Biosciences (NASDAQ:CALA) was a clinical-stage biotechnology company focused on developing small-molecule therapies that target cancer metabolism. The company’s research centered on metabolic pathways that tumors use to support growth and survival, with the goal of improving outcomes for patients with cancer.

Its lead investigational product was telaglenastat (CB-839), an oral inhibitor of glutaminase, an enzyme involved in glutamine metabolism. Calithera evaluated telaglenastat in combination with other treatments for cancers including renal cell carcinoma, triple-negative breast cancer and hematologic malignancies. The company also developed CB-280, an investigational arginase inhibitor intended for potential use in solid tumors.

Founded in 2010 and based in South San Francisco, California, Calithera conducted clinical-development activities primarily in the United States, with research and collaborations involving international pharmaceutical companies. Susan Molineaux, a co-founder, served as the company’s president and chief executive officer for much of its operating history. Calithera later discontinued development activities and ceased operating as an active biotechnology company.

View Calithera Biosciences Profile
Earnings Tools